Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura (efgartigimod alfa and hyaluronidase-qvf), this time for adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback